[Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
T L
TL
Demina
N V
NV
Khachanova
M V
MV
Davydovskaia
N F
NF
Popova
E I
EI
Gusev
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006801:Humans; D007273:Injections, Intramuscular; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000008:administration & dosage / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012074:Remission Induction / Q000379:methods; D055502:Secondary Prevention; D013997:Time Factors; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D011994:Recombinant Proteins; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a